|
🦁
|
Expression of ocular albinism 1 (OA1), 3, 4- dihydroxy- L-phenylalanine (DOPA) receptor, in both neuronal and non-neuronal organs
10 auth.
N. Fukuda,
Saki Naito,
D. Masukawa,
Moemi Kaneda,
H. Miyamoto,
T. Abe,
...
Yui Yamashita,
I. Endo,
F. Nakamura,
Y. Goshima
|
4 |
2015 |
4
🦁
|
|
🐜
|
Adverse events induced by nivolumab and ipilimumab combination regimens
14 auth.
K. Somekawa,
N. Horita,
A. Kaneko,
Y. Tagami,
N. Fukuda,
H. Matsumoto,
H. Namkoong,
Yumi Fujiwara,
K. Minegishi,
T. Fukumoto,
...
Keisuke Watanabe,
Yu Hara,
N. Kobayashi,
Takeshi Kaneko
|
4 |
2022 |
4
🐜
|
|
🐜
|
Clinical Features of Patients with Active Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab
7 auth.
N. Tsurikisawa,
C. Oshikata,
M. Watanabe,
N. Fukuda,
T. Yamaguchi,
Hikari Kiyohara,
...
T. Kaneko
|
3 |
2021 |
3
🐜
|
|
🐜
|
Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis
11 auth.
N. Kobayashi,
S. Katakura,
C. Kamimaki,
K. Somekawa,
N. Fukuda,
Katsushi Tanaka,
...
Keisuke Watanabe,
N. Horita,
Yu Hara,
H. Piao,
T. Kaneko
|
3 |
2021 |
3
🐜
|
|
🐜
|
Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial
19 auth.
H. Matsumoto,
N. Kobayashi,
K. Somekawa,
N. Fukuda,
A. Kaneko,
C. Kamimaki,
S. Kubo,
Katsushi Tanaka,
Y. Tagami,
Shuhei Teranishi,
...
Keisuke Watanabe,
N. Horita,
Yu Hara,
Masaki Yamamoto,
M. Kudo,
Harumi Koizumi,
Kenji Miura,
N. Miyazawa,
T. Kaneko
|
3 |
2021 |
3
🐜
|
|
🦁
|
Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease.
7 auth.
N. Fukuda,
N. Horita,
A. Kaneko,
A. Goto,
T. Kaneko,
E. Ota,
...
Kayleigh Kew
|
3 |
2023 |
3
🦁
|
